AJMC Staff

Median overall survival was not yet reached at a median follow-up of 8.7 months on the company’s ZUMA-1 trial.

The National Organization for Rare Disorders has announced a new, yearlong campaign to raise public awareness of rare diseases. “Do Your Share for Rare” shines a light on people living with a rare disease and provides an opportunity for them to share their story.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

The FDA has approved lenalidomide as maintenance therapy in patients with multiple myeloma following autologous stem cell transplant.

Researchers at the American Cancer Society have found that nonelderly cancer survivors enrolled in high-deductible health plans are more likely to seek a change to a lower-cost prescription medication compared with those without a cancer history.

Population-level judgements on the value of therapies to treat multiple sclerosis don’t adequately depict the differences between how providers and payers view value compared with patients and how patients view value different from one another.

The presentation at HIMSS 2017 comes after a record-breaking year in healthcare data breaches.

A news article on using community health records to improve population wellness was included in the Politico Morning eHealth report. RevCycle Intelligence and Patient Engagement HIT both examined the results of a February article on an asthma education program. Health IT Analytics highlighted the findings of a January article that assessed the role of value-based payment in implementing an evidence-based mental health intervention.

So far, the adverse events have been reported for the 2 fluid-filled designs, not for an air-filed design later approved.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

Pembrolizumab (Keytruda) has received green light from the European Commission for the first-line treatment of a select population of adult patients with metastatic non-small cell lung cancer.